Enanta Pharmaceuticals, Inc.
Clinical trials sponsored by Enanta Pharmaceuticals, Inc., explained in plain language.
Biotech focused on antiviral and respiratory disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill for chronic hives enters first human safety tests Results expected Nov 2026 (estimated)
- New pill could help babies fight RSV faster Results expected Dec 2026 (estimated) May already have reported ↗
-
Can a 5-Day pill tame RSV in the most vulnerable?
Disease control CompletedThis trial tests an experimental antiviral pill, EDP-938, in adults with a confirmed RSV infection who are at high risk for complications—such as those over 65 or with asthma, COPD, or heart failure. Participants take the drug or a placebo once daily for five days. The goal is to…
Phase 2 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New RSV pill shows promise in early human trial
Disease control CompletedThis study tested an experimental oral drug called EDP-323 in 142 healthy adults who were deliberately infected with RSV. The goal was to see if the drug is safe and can reduce the amount of virus in the nose compared to a placebo. Results will help determine if EDP-323 could be …
Phase 2 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC